• Translocations between PD-L1 and the IGH locus, represent a genetic mechanism of PD-L1 overexpression in DLBCL.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the one of the most common and aggressive forms of B-cell lymphomas 1 . At least 2 subtypes of DLBCL can be distinguished by gene expression analysis: the germinal center B-cell like (GCB) and the activated B-cell like (ABC) subtypes, with the latter being characterized by increased disease aggressiveness and worst clinical outcomes 2, 3 . In recent years, the incorporation of anti-CD20 therapeutic antibodies into the standard Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone (CHOP) treatment has contributed to an overall improvement of patient survival [3] [4] [5] . In spite of this, disease relapse is often refractory to the currently available therapies, which marks the necessity for the development of new therapeutic approaches for DLBCL 6 .
Recently, the genomic characterization of DLBCL has been performed in a number studies employing next generation sequencing (NGS) technologies. These studies, along with earlier ones, contributed to the identification of a set of genes/pathways that are frequently targeted by mutations in DLBCL [7] [8] [9] [10] [11] [12] . Moreover, whole genome sequencing (WGS) and RNA sequencing (RNAseq) enabled the identification of novel structural variations (SVs) in DLBCL involving the TP63 and CIITA genes [13] [14] [15] . These translocations may contribute to tumorigenesis in addition to the few well-described, recurrent SVs such as rearrangements involving the proto-oncogenes BCL6, BCL2 and MYC and the immunoglobulin heavy chain (IGH) gene locus [16] [17] [18] .
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Translocations between IGH and proto-oncogenes usually result in upregulation of the latter by bringing them under the control of the potent IGH Eμ and 3' enhancers 19 . These events, especially in GC-related B cell lymphomas, have been suggested to be mainly triggered by aberrant, off target activity of activation-induced cytidine deaminase (AID) 20, 21 . The physiological role of AID is to deaminate cytidine residues within the variable (V) or switch (S) regions of the IGH locus, which is essential for the somatic hypermutation (SHM) or class switch recombination (CSR) processes respectively 22, 23 . During CSR, AID-induced mismatches lead to double-strand breaks (DSBs) in the S regions that are resolved by one of the two major DSB repair mechanisms, the non-homologous end-joining (NHEJ) pathway 24 .
We have previously suggested that defects in the NHEJ pathway might be associated with the formation of translocations involving the IGH locus 25 .
PD-L1 and PD-L2 are signaling molecules expressed on the surface of antigen-presenting cells 26 . Upon interaction with their receptor PD-1 on effector T-cells, they transmit a negative regulatory signal that leads to functional anergy of the T-cells 27 . Various malignancies have been shown to overexpress PD-L1 in order to escape T-cell mediated killing [28] [29] [30] .
In recent years, the introduction of drugs targeting the PD-1-PD-L1/PD-L2 immunemodulatory pathway has shown promising results in the treatment of aggressive malignancies such as melanoma, renal cancer and lung cancer 31 . A study on Hodgkin lymphoma (HL) demonstrated that up to 87% of patients with refractory disease responded to PD-1 blockade 32 . Accordingly, the chromosome 9p24.1 cytoband, which includes the adjacent PD-L1 and PD-L2 genes, was found to be rearranged to the V regions of the IGH locus in a HL derived cell line 33 . In non-Hodgkin lymphomas, alterations affecting the 9p24.1 cytoband were observed in a subset of DLBCLs 33 , but more frequently, in several specific types of large B-
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overexpression was furthermore observed in the aggressive ABC/non-GCB subtype of DLBCL 36, 37 . Moreover, a recent study performed on DLBCL-derived cell lines, demonstrated that PD-1 blockade restores T-cell function in vitro 38 . Together, the PD-1-PD-L1/PD-L2 axis may constitute a target for immunotherapy in refractory and aggressive DLBCL. 
METHODS

Patient cohorts
Chinese cohort
Frozen material corresponding to tumor biopsies from 176 Chinese DLBCL patients were obtained from the Sun Yat-Sen University Cancer Center and the Tianjin Medical University Cancer Institute and Hospital. Matching peripheral blood DNA samples were available for 76 patients. The Epstein-Barr virus (EBV) active infection status was assessed in a subset of samples using Chromogenic in situ hybridization. Additionally, a tissue microarray (TMA) with 100 Chinese DLBCLs was purchased from US Biomax inc (Rockville, MD).
Swedish cohort
The work described in this manuscript has been approved by the Institutional Review Board and the Swedish Central Ethical Review Board. Samples from 64 Swedish DLBCL patients were collected at the Uppsala University Hospital. Formalin-fixed paraffin-embedded (FFPE) tissue was available and tumor tissue cores were organized in TMAs. DNA and RNA from 3 samples were extracted from the FFPE blocks. Further details are provided in the supplemental materials and methods.
American cohort
RNA extraction, RNAseq and quantitative real-time PCR (qPCR)
Total RNA was extracted either with the RNeasy kit (Qiagen) or the Recoverall Total Nucleic Acid Isolation kit. Library preparation and the RNAseq method on the Illumina HiSeq 2000 platform have been described before 43 . The number of fragments per kilobase of transcript per megabase of mapped reads (FPKM) was used to determine relative gene expression levels. Detection of fusion transcripts was enabled by SOAPfuse 44 . RNAseq data was also used for the classification of the two disease subtypes, GCB and ABC based on a published set of genes 45 . Information about qPCR is provided in supplemental materials and methods.
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Detection of cytogenetic alterations by fluorescence in-situ hybridization (FISH)
Fluorescent probes flanking the PD-L1/PD-L2 locus were generated from bacterial artificial chromosome clones RP11-963L, RP11-12D24, RP11-207C16 and RP11-845C2, labeled with spectrum green and orange dUTPs (Enzo lifesciences, Farmingdale, NY). Vysis LSI IGH (Abbott Molecular, Abbott Park, IL) break-apart rearrangement probes were used for analysis of the IGH locus. Treatment and probe hybridization were performed as previously described 46 . Further details are provided in the supplemental materials and methods.
Detection of PD-L1, Human leukocyte antigen (HLA) class I and CD8 by IHC
The antibodies used for IHC were a PD-L1 monoclonal antibody (#13684, clone E1L3N, Cell signaling, Beverly, MA), a PD-L2 polyclonal antibody (SAB3500395, Sigma-Aldrich, St.
Louis, MO), a CD8 monoclonal antibody (M7103, clone C8/144B, DAKO) and the HLA I assessing antibodies HCA2 and HC10 [47] [48] [49] (Nordic MUbio, Susteren, Netherlands). Further details are provided in the supplemental materials and methods.
1 1 translocations between the IGH and the PD-L1 loci in one of the samples, DL48. This is, to our knowledge, the first time that PD-L1 is identified as a fusion partner for IGH in DLBCL.
RESULTS
WGS reveals rearrangements involving the PD-L1/PD-L2 locus
The finding of WGS was subsequently validated by breakpoint-specific PCR analysis using primers surrounding the fusion points between the two loci ( Fig. 1A, B) . The breakpoint within the IGH locus was situated in the Sμ region, which was already rearranged to the Sγ1 region through CSR, whereas on chromosome 9 the breakpoint was located in the intron separating the 6 th and 7 th exons of the main transcript of PD-L1 (NM_014143). Of note, AIDtargeting motifs (WRC/GYW) were furthermore identified on both sides of the breakpoints, suggesting that illicit activities of AID during CSR might be responsible for the initiation of this translocation event (Fig. S3 ). FISH analysis on FFPE slides derived from the DL48 tumor showed the presence of split signals of PD-L1 and IGH loci in 52% and 46% of the nuclei counted, respectively. This supports the presence of the rearrangement in the main tumor
clone. An additional FISH experiment employing four-color probes further demonstrated the fusion between the two loci and the balanced nature of the rearrangements (Fig. 1C ).
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The fusion transcript that resulted from the translocation of the PD-L1 and IGH loci was subsequently identified by RNAseq, and confirmed by PCR and Sanger sequencing. This transcript contained the first 6 exons of PD-L1 together with the 3 rd exon of IGHG1. The last exon of PD-L1, which was missing from this fusion transcript, encodes for the final 7 amino acids of the peptide chain, located in the intracellular domain 50, 51 , without any known function 27 . RNAseq reads for each PD-L1 exon (Fig. S4A ) and an allele-specific qPCR approach further illustrated that the majority of PD-L1 expression in this tumor originated from the fusion transcript, suggesting that the translocation is a driver event for PD-L1 expression (Fig. S4B ).
The WGS analysis of the 20 Chinese DLBCLs furthermore discovered a second translocation juxtaposing the PD-L1/PD-L2 locus to TP63. This translocation was also balanced and the breakpoints were located between the 5 th and 6 th exons of PD-L1, and the 1 st and 2 nd exons of TP63 (Fig. S5A, B) . Moreover, a number of copy number alterations (CNA) were discovered and are summarized in Fig. S6 .
Cytogenetic analysis on extended DLBCL cohorts
We employed a FISH assay in order to identify additional cytogenetic alterations affecting the and 7 translocations (4%) (Fig. 2B) . In samples that underwent both FISH and WGS, the data concerning the status of the PD-L1/PD-L2 locus was concordant (Fig. S6) . Fisher's exact test, P=0.0016, Fig. 2C ). Notably, translocations and amplifications in the PD-L1/PD-L2 locus were exclusively found in non-GCB samples (Fig. 2C) or ABC samples in the American cohort where GCB/ABC classification based on gene expression array was available.
WGS of selected samples in the expanded cohort
To further characterize the additional samples presenting a break or amplification of the PD-L1/PD-L2 locus identified by the FISH analysis, WGS was performed on tumor samples from 4 of the 7 affected patients, for which DNA was available (SL24, SL55, 2168 and 2171). A mean sequencing depth of 32.2X was achieved and 96.4% of the genome was covered by at least 10 reads (Fig. S2C ). WGS and breakpoint specific PCR confirmed the existence of translocations in the PD-L1/PD-L2 locus in two of these samples (2168 and SL55) and identified the translocation partners. Sample 2168 had a breakpoint in the intergenic region 1 4 between PD-L1 and PD-L2. Interestingly, the translocation partner here was PIM1, a protooncogene that is recurrently mutated in DLBCL and constitutes a target of aberrant SHM 52 ( Fig. S5C, D) . The translocation was balanced, resulting in 2 fusion chromosomes joining PD-L1 with the telomeric half and PD-L2 with the centromeric part of PIM1 respectively. In sample SL55, the location of the breakpoint in the PD-L1/PD-L2 locus was at the 3' end of PD-L2 (Fig. S5E) . The translocation partner was IGH (Sμ), thus bringing the total number of PD-L1/PD-L2 -IGH translocations to 2. In the rearrangements identified in samples 2168
and SL55, the entire PD-L1 and/or PD-L2 genes are being juxtaposed to their translocation partners and thus no fusion transcripts are generated (confirmed by RNAseq analysis). In one additional sample, SL24, breaks in the PD-L1/PD-L2 and IGH loci were identified by WGS, in accordance with the FISH data. However, we were not able to validate it by breakpoint specific PCRs, probably due to DNA degradation in this sample. Copy number variation analysis from the WGS data confirmed the amplification of the PD-L1 locus in sample 2171. and IGH loci (Fig. S8) , whereas the mRNA levels of PD-L1 measured by RNAseq appeared to be low (Fig. S7) . This may reflect the low quality of RNA of this particular sample (prepared from FFPE). By pooling together all samples that evaluated by both IHC and genetic/cytogenetic analyses, a strong association between PD-L1 protein expression and alterations in the PD-L1/PD-L2 locus was observed (Fisher's exact test, P<0.0001; Fig. 4) .
PD-L1/PD-L2 gene expression analysis
Furthermore, the PD-L1 expression was more frequently observed in non-GCB as compared to GCB samples (Fig. S9) . PD-L2 expression was assessed in 84 samples and in concordance with RNA expression data, no association was observed between cytogenetic alterations and PD-L2 protein expression (Fig. S10) . 53, 54 . In 9 of the HLA class I negative samples, we were able to cross the IHC data with RNA and genomic sequencing results and found that 7 of those samples either express B2M in levels lower than the sample median, or harbor B2M mutations (identified by WGS), or both (Fig. S11 ). This may explain the loss of HLA class I expression in these samples. The expression of PD-L1 protein has previously been associated with rapid progression of disease in various cancers [56] [57] [58] including DLBCL 37 . Our results are in general agreement with those reports and indicate that patients with a more aggressive form of disease (non-GCB) could potentially benefit from treatments targeting the PD-1-PD-L1/PD-L2 axis. Previous work also suggested that preexisting infiltration by CD8 + T-cell is a prerequisite for a successful response to PD-1 blockade therapy 59 . Furthermore, the presence of neo-antigens resulting from an increased mutation load seems to enhance the T-cell infiltration 60, 61 .
Moreover, studies from colorectal carcinoma showed that patients with impaired mismatch repair (MMR) respond better to the anti-PD-1 therapy 62 . Although the mechanisms 1 8 responsible for this relation are not clear, it is hypothesized that the improved responsiveness to immunotherapy is due to an increase in the number of neo-antigens as a result of the higher mutational load associated with the impaired MMR 25, 63 . Aberrant SHM as well as mutations in the MMR pathway contribute to an increase of the mutation load in DLBCL 9, 52 . Notably, sample DL48, where the original PD-L1-IGH translocation was identified, carries a somatic deleterious mutation in the MSH2 gene, a major component of MMR and shows an increased number of somatic mutations in the coding genome 25 . In addition, histological examination confirmed CD8 + T-cell infiltration in the sample. Taken together, a subset of DLBCLs,
represented by DL48, is likely to respond well to the anti-PD-1 -PD-L1 therapy.
The effect of PD-1-PD-L1 blockade therapy is likely to be dependent on the expression of . Regardless of the mechanism, the preference of expression of PD-L1 in the non-GCB/ABC disease subtype suggests that immunotherapies blocking PD-1 and PD-L1 may be promising in patients suffering from this aggressive subtype of disease. Of note, we also attempted to classify our samples into the GCB and ABC disease subtypes by RNAseq based on the set of genes described previously 45 . However, approximately one quarter of the samples could not be grouped to either GCB or ABC, as they displayed an intermediate expression pattern (Fig. S13A) , suggesting that the current classification for DLBCL might still be oversimplified. In addition, we also observed a distinctive RNA expression signature in tumors overexpressing PD-L1, which might also reflect an altered tumor microenvironment of these tumors (Fig. S13B) . Further integration of genomic, transcriptomic and clinical data would be expected to provide us a more comprehensive picture of DLBCL. 1
In summary, our data indicate that genetic alterations affecting the PD-L1/PD-L2 locus, especially translocations and amplification, lead to the overexpression of the immunemodulatory factor PD-L1. In addition, our data suggest that patients with an aggressive subtype of disease may benefit from therapies blocking the PD-1-PD-L1/PD-L2 interaction.
However, the factors that can predict the efficacy of these therapies are still not fully elucidated. Fisher's exact test was used for comparison of the frequency of these alterations between GCB and non-GCB samples. 
